Benzinga’s Top Pre-Market Losers (BSX, SQNM, UWBK, PSEC)
March 16, 2010 7:23 AM
Boston Scientific Corporation (NYSE: BSX) decreased 0.15% to $6.79 in the pre-market session. Boston Scientific announced yesterday that it has received Australian Therapeutic Goods Administration approval for its PROMUS Element and TAXUS Element Stent Systems, the Company's drug eluting stent (DES) technology. The 52-week trading range for BSX is $6.31 - $11.77. Boston Scientific has declined over 39% in the last six months.
Sequenom, Inc. (NASDAQ: SQNM) tumbled 15.98% to $6.52 in the pre-market session. Sequenom reported yesterday a fourth quarter total revenue of $10.8 million, as compared to $12.2 million for the same quarter last year. Net loss for the fourth quarter of 2009 was $18.4 million, or $0.30 per share, as compared to $15.4 million, or $0.25 per share, in the year ago period. SQNM closed at $7.76 in the last trading session. The 52-week trading range for SQNM is $2.55 - $16.80.
United Western Bancorp, Inc. (NASDAQ: UWBK) fell 3.51% to $2.20 in the pre-market session. United Western Bancorp reported a fourth quarter net loss of $40.6 million or $1.40 per share, as compared to a net income of $2.0 million or $0.28 per share in the year-ago quarter. The 52-week trading range for UWBK is $2.17 -$10.85. UWBK has declined over 54% in the last year.
Prospect Capital Corporation (NASDAQ: PSEC) declined 0.16% to $12.39 in the pre-market session. Prospect Capital closed at $12.41 in the last trading session. In the last six months, PSEC has surged over 19%. The 52-week trading range for PSEC is $7.23 - $13.22.
